Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy

In 2017, the International Parkinson and Movement Disorder Society put forward new clinical criteria for the diagnosis of PSP, recognizing diverse PSP phenotypes. In this study, we compared the sensitivity and specificity of the new criteria with the National Institutes of Neurological Disease and Society for Progressive Supranuclear Palsy criteria at different times.

[1]  B. Boeve,et al.  Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype , 2018, Acta Neuropathologica.

[2]  John L. Robinson,et al.  Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated , 2018, Brain : a journal of neurology.

[3]  W. Poewe,et al.  Validation of the MDS clinical diagnostic criteria for Parkinson's disease , 2018, Movement disorders : official journal of the Movement Disorder Society.

[4]  B. Ghetti,et al.  Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains , 2017, Alzheimer's Research & Therapy.

[5]  Murray Grossman,et al.  Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria , 2017, Movement disorders : official journal of the Movement Disorder Society.

[6]  J. Rowe,et al.  Radiological biomarkers for diagnosis in PSP: Where are we and where do we need to be? , 2017, Movement disorders : official journal of the Movement Disorder Society.

[7]  Luca Passamonti,et al.  18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.

[8]  Hanna Cho,et al.  Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[9]  Anthony J. Spychalla,et al.  [18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.

[10]  G. Ebersbach,et al.  An autopsy-confirmed case of progressive supranuclear palsy with predominant postural instability , 2016, Acta neuropathologica communications.

[11]  M. Schain,et al.  Increased basal ganglia binding of 18 F‐AV‐1451 in patients with progressive supranuclear palsy , 2016, Movement disorders : official journal of the Movement Disorder Society.

[12]  Keith A. Josephs,et al.  The clinical spectrum and natural history of pure akinesia with gait freezing , 2016, Journal of Neurology.

[13]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[14]  Richard J. Binney,et al.  Features of Patients With Nonfluent/Agrammatic Primary Progressive Aphasia With Underlying Progressive Supranuclear Palsy Pathology or Corticobasal Degeneration. , 2016, JAMA neurology.

[15]  D. Dickson,et al.  Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSP‐C , 2016, Movement disorders : official journal of the Movement Disorder Society.

[16]  R. Barker,et al.  Review: The spectrum of clinical features seen with alpha synuclein pathology , 2016, Neuropathology and applied neurobiology.

[17]  David T. Jones,et al.  Classification and clinicoradiologic features of primary progressive aphasia (PPA) and apraxia of speech , 2015, Cortex.

[18]  E. Tolosa,et al.  The phenotypic spectrum of progressive supranuclear palsy: A retrospective multicenter study of 100 definite cases , 2014, Movement disorders : official journal of the Movement Disorder Society.

[19]  H. Shill,et al.  Concomitant pathologies among a spectrum of parkinsonian disorders. , 2014, Parkinsonism & related disorders.

[20]  J. Hodges,et al.  Edinburgh Research Explorer Validation of the New Consensus Criteria for the Diagnosis of Corticobasal Degeneration , 2022 .

[21]  A. Lees,et al.  Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant , 2014, Neuropathology and applied neurobiology.

[22]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[23]  J. Gunter,et al.  Midbrain atrophy is not a biomarker of progressive supranuclear palsy pathology , 2013, European journal of neurology.

[24]  D. Neary,et al.  Sensitivity and specificity of FTDC criteria for behavioral variant frontotemporal dementia , 2013, Neurology.

[25]  Mark Hallett,et al.  Criteria for the diagnosis of corticobasal degeneration , 2013, Neurology.

[26]  C. Jack,et al.  Neuroanatomical correlates of the progressive supranuclear palsy corticobasal syndrome hybrid , 2012, European journal of neurology.

[27]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[28]  B. Boeve,et al.  Neuropathological features of corticobasal degeneration presenting as corticobasal syndrome or Richardson syndrome. , 2011, Brain : a journal of neurology.

[29]  Dennis W. Dickson,et al.  Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau) , 2011, Journal of Molecular Neuroscience.

[30]  J. Hodges,et al.  Neuropathological background of phenotypical variability in frontotemporal dementia , 2011, Acta Neuropathologica.

[31]  Jennifer L. Whitwell,et al.  Corticobasal degeneration: a pathologically distinct 4R tauopathy , 2011, Nature Reviews Neurology.

[32]  B. Miller,et al.  Classification of primary progressive aphasia and its variants , 2011, Neurology.

[33]  Joseph R Duffy,et al.  Apraxia of speech and nonfluent aphasia: a new clinical marker for corticobasal degeneration and progressive supranuclear palsy , 2008, Current Opinion in Neurology.

[34]  Charles DeCarli,et al.  Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia (bvFTD): Current Limitations and Future Directions , 2007, Alzheimer disease and associated disorders.

[35]  Jennifer L. Whitwell,et al.  Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. , 2006, Brain : a journal of neurology.

[36]  Joseph James Duffy,et al.  Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP , 2006, Neurology.

[37]  Joseph James Duffy,et al.  Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia , 2005, Neurocase.

[38]  Niall Quinn,et al.  Accuracy of clinical diagnosis of progressive supranuclear palsy , 2004, Movement disorders : official journal of the Movement Disorder Society.

[39]  D. Dickson,et al.  Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank , 2003, Movement disorders : official journal of the Movement Disorder Society.

[40]  T Lashley,et al.  Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. , 2002, Brain : a journal of neurology.

[41]  D. Dickson.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration , 1999, Journal of Neurology.

[42]  J. P. Brandel,et al.  Accuracy of the Clinical Diagnosis of Corticobasal Degeneration , 1997, Neurology.

[43]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[44]  I Litvan,et al.  Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[45]  I Litvan,et al.  Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.

[46]  Y Agid,et al.  Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. , 1990, Archives of neurology.

[47]  J. Olszewski,et al.  Progressive Supranuclear Palsy: A Heterogeneous Degeneration Involving the Brain Stem, Basal Ganglia and Cerebellum With Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia and Dementia , 1964 .

[48]  Young T. Hong,et al.  18 FAV-1451 positron emission tomography in Alzheimer ’ s disease and progressive supranuclear palsy , 2017 .

[49]  G. Höglinger,et al.  The phenotypic spectrum of progressive supranuclear palsy. , 2016, Parkinsonism & related disorders.

[50]  I Litvan,et al.  Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. , 1997, Brain : a journal of neurology.

[51]  E. Tolosa,et al.  Clinical diagnosis and diagnostic criteria of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). , 1994, Journal of neural transmission. Supplementum.